Court endorses interim injunction on generic drugs' fabrication case

Published: 2006-11-10 06:58:00

Updated: 2006-11-10 06:58:00

Recently, Seoul District Court gave the green light to an interim injunction filed by six pharmaceutical companies against the Korea Food and Drug Administration's administrative order to retract approval for 17 problematic generic drugs, banning pharmaceutical companies from manufacturing and se...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK